Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of OPC-1085EL in Healthy Male Volunteers
NCT02108288Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of Mikeluna in Glaucoma and ocular hypertension (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration (Cmax) of Carteolol at Day 7 and Maximum Plasma Concentration (Cmax) of Latanoprost Acid at Day 7. Started Apr 2014; status: completed.
02
Drugs
Mikeluna
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT02108288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02108288.